Cost-Effective HIV PrEP: CAB-LA Transforms Prevention

Summary

Cabotegravir long-acting (CAB-LA) delivers a cost-effective HIV PrEP solution. It reduces infections and supports the Ending the HIV Epidemic (EHE) initiative. This review examines CAB-LA’s published economic and health benefits. It guides pharmaceutical executives and health policymakers to optimize PrEP strategies for diverse populations.

Why CAB-LA Excels in HIV Prevention

HIV remains a major U.S. public health issue. In 2019, nearly 37,000 new diagnoses occurred, disproportionately affecting underserved groups. Only 23% of eligible individuals use oral PrEP due to adherence challenges. Approved in 2021, CAB-LA outperforms oral PrEP. HPTN 083 and 084 trials show 66% and 88% reductions in HIV-1 acquisition for MSM/TGW and cisgender women, respectively. CAB-LA’s injectable format addresses adherence barriers, making it a game-changer.

How Cost-Effective Is CAB-LA?

CAB-LA proves cost-effective compared to generic oral FTC/TDF. It prevents 4.5 more HIV-1 infections per 100 PrEP users. This saves 0.2 quality-adjusted life-years (QALYs) per person. CAB-LA’s PrEP costs are higher ($54,631 vs. $4,028). Yet, it cuts HIV management costs by $42,517, adding $9,476 per person. The incremental cost-effectiveness ratio (ICER) is $46,843 per QALY, below the $100,000 threshold. Sensitivity analyses confirm stability. CAB-LA is cost-effective in 85% of simulations. It is cost-saving for cisgender women and African American/Black MSM, aligning with EHE goals.

Allopurinol Designated an Orphan Drug for Marfan Syndrome

May 30, 2025May 30, 2025 João L. Carapinha

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

May 30, 2025May 30, 2025 João L. Carapinha

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-Related Cancer Trends in South Africa 2011-2021

May 30, 2025May 30, 2025 Rene Pretorius

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth